https://www.selleckchem.com/pr....oducts/Romidepsin-FK
46 recurrences/year; p less then 0.001) and MTX (1.54 recurrences/year versus 4.17/year; p = 0.008). Patients under ADA for ophthalmologic purposes (n = 2) did not experience any recurrence. CONCLUSION We report an open-label strategy to prevent the recurrences of HLA-B27-associated AU. First-line sulfasalazine reduced uveitis relapses. The use of anti-TNFα agents for ophthalmologic purposes was unnecessary with rare exceptions.Food safety crises involving persistent organic pollutants (POPs) lead to systematic slaughter of liv
Me gusta
Comentario
Compartir
